Resource Logo
AIDS Weekly Plus

Researchers from French National Academy of Medicine Report Details of New Studies and Findings in the Area of HIV/AIDS




 



2013 OCT 7 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Researchers detail new data in Immune System Diseases and Conditions. According to news reporting out of Paris, France, by NewsRx editors, research stated, "The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Merieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs)."

Our news journalists obtained a quote from the research from the French National Academy of Medicine, "The production of cross-reactive bnAbs is one of the greatest challenges in HIV-1 vaccine development. In natural HIV infection, bnAbs are observed in only a minority of infected individuals and take a few years to develop. This report presents a comprehensive review of how these Abs arise, the possible role of viral evolution, and the activation and maturation requirements of B cell lines that lead to their production. Passive immunization with bnAbs provides efficient, cross-clade protection against simian/human immunodeficiency chimeric virus (SHIV) challenges in nonhuman primates. Despite many efforts to design immunogens that elicit them by active immunization, no immunogen other than HIV itself has yet been able to elicit a bnAb response."

According to the news editors, the research concluded: "For this reason, innovative approaches are under investigation, including their production in the body through a gene delivery approach, vector immunoprophylaxis."

For more information on this research see: Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Merieux Conference Center, Veyrier du Lac, France, 5-7 November 2012. Vaccine, 2013;31(29):2979-83. (Elsevier - www.elsevier.com; Vaccine - www.journals.elsevier.com/vaccine)

Our news journalists report that additional information may be obtained by contacting M.P. Girard, French National Academy of Medicine, 16 rue Bonaparte, 75006 Paris, France. Additional authors for this research include V. Picot, C. Longuet and G.J Nabel (see also Immune System Diseases and Conditions).

Keywords for this news article include: Paris, France, Europe, HIV/AIDS, Vaccines, Virology, Immunology, RNA Viruses, Retroviridae, Blood Proteins, HIV Infections, Immunoglobulins, Serum Globulins, Vertebrate Viruses, Biological Products, Primate Lentiviruses, Neutralizing Antibodies, Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC



 


Copyright © 2013 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in October 7, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.